{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T18:00:42Z","timestamp":1722016842486},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Phosphate retention and hyperphosphataemia are associated with increased mortality in patients with chronic kidney disease (<jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>). We tested the use of cross\u2010linked iron chitosan <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">CH<\/jats:styled-content>\u2010FeCl) as a potential phosphate chelator in rats with <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>. We evaluated 96 animals, divided equally into four groups (control, <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> CH<\/jats:styled-content>\u2010FeCl and <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CH<\/jats:styled-content>\u2010FeCl), over 7 weeks. We induced <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> by feeding animals an adenine\u2010enriched diet (0.75% in the first 4 weeks and 0.1% in the following 3 weeks). We administered 30 mg\/kg daily of the test polymer, by gavage, from the third week until the end of the study. All animals received a diet supplemented with 1% phosphorus. Uraemia was confirmed by the increase in serum creatinine in week 4 (36.24 \u00b1 18.56 <jats:italic>versus<\/jats:italic> 144.98 \u00b1 22.1 \u03bcmol\/L; <jats:italic>p<\/jats:italic> = 0.0001) and week 7 (41.55 \u00b1 22.1 <jats:italic>versus<\/jats:italic> 83.98 \u00b1 18.56 \u03bcmol\/L; <jats:italic>p<\/jats:italic> = 0.001) in <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> animals. Rats from the <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> group treated with <jats:styled-content style=\"fixed-case\">CH<\/jats:styled-content>\u2010FeCl had a 54.5% reduction in serum phosphate (6.10 \u00b1 2.23 <jats:italic>versus<\/jats:italic> 2.78 \u00b1 0.55 mmol\/L) compared to a reduction of 25.6% in the untreated <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> group (4.75 \u00b1 1.45 <jats:italic>versus<\/jats:italic> 3.52 \u00b1 0.74 mmol\/L, <jats:italic>p<\/jats:italic> = 0.021), between week 4 and week 7. At week 7, renal function in both <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> groups was similar (serum creatinine: 83.98 \u00b1 18.56 <jats:italic>versus<\/jats:italic> 83.10 \u00b1 23.87 \u03bcmol\/L, <jats:italic>p<\/jats:italic> = 0.888); however, the <jats:styled-content style=\"fixed-case\">CH<\/jats:styled-content>\u2010FeCl\u2010treated rats had a reduction in phosphate overload measured by fractional phosphate excretion (<jats:styled-content style=\"fixed-case\">FEP<\/jats:styled-content>i) (0.71 \u00b1 0.2 <jats:italic>versus<\/jats:italic> 0.4 \u00b1 0.16, <jats:italic>p<\/jats:italic> = 0.006) compared to the untreated <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> group. Our study demonstrated that <jats:styled-content style=\"fixed-case\">CH<\/jats:styled-content>\u2010FeCl had an efficient chelating action on phosphate.<\/jats:p>","DOI":"10.1111\/bcpt.12849","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T11:22:42Z","timestamp":1500549762000},"page":"120-125","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chitosan\u2010Fe (<scp>III<\/scp>) Complex as a Phosphate Chelator in Uraemic Rats: A Novel Treatment Option"],"prefix":"10.1111","volume":"122","author":[{"given":"Wander Barros","family":"do Carmo","sequence":"first","affiliation":[{"name":"Division of Clinical Medicine of the Federal University of Juiz de Fora Juiz de Fora Brazil"},{"name":"Interdisciplinary Center for Laboratory Animal Studies (NIDEAL) Center for Reproductive Biology Federal University of Juiz de Fora Juiz de Fora Brazil"},{"name":"Interdisciplinary Center for Studies and Research in Nephrology (NIEPEN) Federal University of Juiz de Fora Juiz de Fora Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara Bruna Abreu","family":"Castro","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center for Laboratory Animal Studies (NIDEAL) Center for Reproductive Biology Federal University of Juiz de Fora Juiz de Fora Brazil"},{"name":"Interdisciplinary Center for Studies and Research in Nephrology (NIEPEN) Federal University of Juiz de Fora Juiz de Fora Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00f3vis Ant\u00f4nio","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Nucleus of Chemical\u2010Pharmaceutical Research (NIQFAR) of the University of Vale do Itaja\u00ed Itaja\u00ed Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melani Ribeiro","family":"Cust\u00f3dio","sequence":"additional","affiliation":[{"name":"Division of Nephrology University of S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helady","family":"Sanders\u2010Pinheiro","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center for Laboratory Animal Studies (NIDEAL) Center for Reproductive Biology Federal University of Juiz de Fora Juiz de Fora Brazil"},{"name":"Interdisciplinary Center for Studies and Research in Nephrology (NIEPEN) Federal University of Juiz de Fora Juiz de Fora Brazil"},{"name":"Division of Nephrology Federal University of Juiz de Fora Juiz de Fora Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.12.006"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-015-0189-z","article-title":"The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study","volume":"16","author":"Fraser SD","year":"2015","journal-title":"BMC Nephrol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002009"},{"key":"e_1_2_7_5_1","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease\u2010Mineral and Bone Disorder (CKD\u2010MBD)","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.03.042"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08621209"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008040349"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0054-y"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.841667"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000337087"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5414\/CN108209","article-title":"Oral phosphate binders in CKD \u2013 is calcium the (only) answer?","volume":"81","author":"Goldsmith D","year":"2014","journal-title":"Clin Nephrol"},{"key":"e_1_2_7_13_1","first-page":"1","article-title":"New conclusions regarding comparison of sevelamer and calcium\u2010based phosphate binders in coronary\u2010artery calcification for dialysis patients: a meta\u2010analysis of randomized controlled trials","volume":"10","author":"Wang C","year":"2015","journal-title":"PLoS ONE"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.10.055"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.10.014"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014020212"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315589934"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfu139"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357001774552"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(01)00727-X"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00527.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1081\/JLC-100103441"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000183992"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2007.00844.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq682"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471141755.pha04bs59"},{"key":"e_1_2_7_27_1","first-page":"2555","volume-title":"Diseases of the Kidney","author":"Anderson S","year":"1997"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.5.961"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2011.649657"},{"key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000380969","article-title":"Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end\u2010stage renal disease patients","volume":"185","author":"Shigematsu T","year":"2015","journal-title":"Contrib Nephrol"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12864"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.483"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.014"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70221-0"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12202"},{"key":"e_1_2_7_36_1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.ajkd.2015.03.013","article-title":"The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial","volume":"66","author":"Buren PN","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_7_37_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10157-016-1299-z","article-title":"Dose\u2010response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo\u2010controlled, double\u2010blind, Phase II study","volume":"21","author":"Koiwa F","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv006"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.05.015"},{"key":"e_1_2_7_40_1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-0035-1569328","article-title":"Comparison of phosphate binding capacities of PA21, a novel phosphate binder, with those of other phosphate binders in vitro and in vivo","volume":"66","author":"Yaguchi A","year":"2016","journal-title":"Drug Res (Stuttg)"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.06.004"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2014.938544"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00290109"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft280"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12849","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:31:35Z","timestamp":1695573095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/bcpt.12849"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12849","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]},"assertion":[{"value":"2017-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}